Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
10 janv. 2022 08h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 16h01 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
20 déc. 2021 07h00 HE
|
Cara Therapeutics, Inc.
KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics,...
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
18 nov. 2021 08h30 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical...
Cara Therapeutics to Present at Upcoming Investor Conferences
09 nov. 2021 16h30 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Third Quarter 2021 Financial Results
08 nov. 2021 16h01 HE
|
Cara Therapeutics, Inc.
– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug...
Cara Therapeutics Announces CEO Transition
03 nov. 2021 08h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
01 nov. 2021 16h15 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
04 oct. 2021 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
29 sept. 2021 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...